Oral GLP-1 Drugs Lead Obesity Treatment Revolution in $126B Market
TL;DR
The race to develop oral GLP-1 receptor (GLP-1R) drugs for obesity is intensifying, with four products currently in Phase III trials. This market, projected to exceed $126 billion by 2030, is dominated by Novo Nordisk and Eli Lilly, who are transitioning from successful injectable treatments to oral alternatives. Novo Nordisk's Rybelsus and NN-9932, along with Eli Lilly's orforglipron calcium, are leading candidates, while Jiangsu Hengrui's HRS-953 represents a new entrant. The demand for effective obesity treatments is driven by rising global obesity rates.
- Four oral GLP-1R products in Phase III trials as race intensifies Clinical Trials Arena
- Semaglutide Rocketing Past Statins as Millions Eligible Medscape
- Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market FiercePharma
- Seven unanswered questions about blockbuster weight-loss drugs Nature.com
- GLP-1 RA antiobesity medications: Predictions for the future Medical Economics
Want the full story? Read the original reporting
Read on Clinical Trials Arena